Radiotherapy and Oncology最新文献

英文中文

3547: Upright: potential challenges 3547：直立：潜在挑战

IF 5.7 1区医学 Q1 ONCOLOGY

Radiotherapy and Oncology

Pub Date : 2024-08-30 DOI: 10.1016/s0167-8140(24)03451-0

Lennart Volz

引用次数: 0

3542: Toxicity of SBRT 3542：SBRT 的毒性

IF 5.7 1区医学 Q1 ONCOLOGY

Radiotherapy and Oncology

Pub Date : 2024-08-30 DOI: 10.1016/s0167-8140(24)03447-9

Christina Schröder

引用次数: 0

3597: The target: Who needs what? 3597：目标：谁需要什么？

IF 5.7 1区医学 Q1 ONCOLOGY

Radiotherapy and Oncology

Pub Date : 2024-08-30 DOI: 10.1016/s0167-8140(24)03467-4

Floris J. Pos

引用次数: 0

11: Register data on long-term morbidity after prostate ultra-hypofractionation in the HYPO-RT-PC trial 11：HYPO-RT-PC试验中前列腺超短波治疗后长期发病率的登记数据

IF 5.7 1区医学 Q1 ONCOLOGY

Radiotherapy and Oncology

Pub Date : 2024-08-30 DOI: 10.1016/s0167-8140(24)03483-2

Astrid E. Persson, Elisabeth Kjellén, Hans Garmo, Gabriel Adrian, Pär Stattin, Anders Widmark, Per Nilsson, Adalsteinn Gunnlaugsson

引用次数: 0

3541: Toxicity of brachytherapy 3541：近距离放射治疗的毒性

IF 5.7 1区医学 Q1 ONCOLOGY

Radiotherapy and Oncology

Pub Date : 2024-08-30 DOI: 10.1016/s0167-8140(24)03446-7

Piotr Wojcieszek

引用次数: 0

Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable esophageal squamous cell carcinoma: A pooled analysis of randomized clinical trials 可切除食管鳞状细胞癌新辅助化疗或放化疗后的生存率：随机临床试验的汇总分析。

IF 4.9 1区医学 Q1 ONCOLOGY

Radiotherapy and Oncology

Pub Date : 2024-08-30 DOI: 10.1016/j.radonc.2024.110517

Background

The comparison of neoadjuvant chemoradiotherapy (nCRT) versus neoadjuvant chemotherapy (nCT) for locally advanced esophageal squamous cell carcinoma (ESCC) remains inconclusive, and the optimal regimen is still under investigation.

Methods

Prospective randomized clinical trials were systematically searched in electronic databases from inception to Oct 2023. A graphical reconstructive algorithm was employed to extract time-to-event outcomes from Kaplan-Meier curves presented in the original studies. Using reconstructed individual patient data, summary overall survival (OS) and disease progression-free survival (DFS) for nCRT versus nCT, primarily doublet chemotherapy were recalculated. Hazard Ratios (HRs) of OS and DFS reported were also pooled by the fixed-effects model.

Results

A total of 6 randomized clinical trials comprising 1162 patients were included in our analysis. In the individual patient data (IPD) pooled analysis, a significant OS benefit was found for nCRT in ESCC (HR=0.81, 95 %CI:0.67–0.98, p=0.029), compared with the treatment of nCT. The median overall survival time were 53 months (95 %CI:41.9–67.7 m) and 66 months(95 %CI:57.2-NA) respectively in the nCT and nCRT groups. Additionally, a significant improvement in PFS for nCRT compared to nCT in the IPD pooled analysis (HR=0.79,95 %CI:0.64–0.98; p=0.027). Consistent with above results, the pooled HRs of OS and DFS for nCRT versus nCT were 0.78 (95 % CI 0.65–0.92, p=0.004) and 0.79 (95 % CI: 0.65–0.97, p=0.02), respectively. Notably, no substantial heterogeneity across studies was observed.

Conclusions

Our findings indicate that nCRT offers better survival outcomes for ESCC, at least when compared to neoadjuvant doublet chemotherapy.This evidence continues to support the clinical practice of employing nCRT in locally advanced resectable ESCC.

背景：新辅助化放疗（nCRT）与新辅助化疗（nCT）治疗局部晚期食管鳞状细胞癌（ESCC）的比较仍无定论，最佳方案仍在研究中：方法：在电子数据库中系统检索了从开始到2023年10月的前瞻性随机临床试验。采用图形重构算法从原始研究中的 Kaplan-Meier 曲线中提取时间到事件的结果。利用重建的患者个体数据，重新计算了nCRT与nCT（主要是双联化疗）的总生存期（OS）和无疾病进展生存期。报告的OS和DFS的危险比（HRs）也通过固定效应模型进行了汇总：我们的分析共纳入了 6 项随机临床试验，共 1162 名患者。在患者个体数据（IPD）汇总分析中，与nCT治疗相比，nCRT治疗ESCC的OS获益显著（HR=0.81，95 %CI:0.67-0.98，p = 0.029）。nCT组和nCRT组的中位总生存时间分别为53个月（95 %CI：41.9-67.7 m）和66个月（95 %CI：57.2-NA）。此外，在 IPD 汇总分析中，与 nCT 相比，nCRT 的 PFS 有明显改善（HR=0.79,95 %CI:0.64-0.98; p = 0.027）。与上述结果一致，nCRT 与 nCT 相比，OS 和 DFS 的汇总 HR 分别为 0.78（95 % CI 0.65-0.92，p = 0.004）和 0.79（95 % CI：0.65-0.97，p = 0.02）。值得注意的是，各研究之间未发现实质性异质性：我们的研究结果表明，与新辅助双联化疗相比，nCRT能为ESCC提供更好的生存结果。

{"title":"Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable esophageal squamous cell carcinoma: A pooled analysis of randomized clinical trials","authors":"","doi":"10.1016/j.radonc.2024.110517","DOIUrl":"10.1016/j.radonc.2024.110517","url":null,"abstract":"<div><h3>Background</h3><p>The comparison of neoadjuvant chemoradiotherapy (nCRT) versus neoadjuvant chemotherapy (nCT) for locally advanced esophageal squamous cell carcinoma (ESCC) remains inconclusive, and the optimal regimen is still under investigation.</p></div><div><h3>Methods</h3><p>Prospective randomized clinical trials were systematically searched in electronic databases from inception to Oct 2023. A graphical reconstructive algorithm was employed to extract time-to-event outcomes from Kaplan-Meier curves presented in the original studies. Using reconstructed individual patient data, summary overall survival (OS) and disease progression-free survival (DFS) for nCRT versus nCT, primarily doublet chemotherapy were recalculated. Hazard Ratios (HRs) of OS and DFS reported were also pooled by the fixed-effects model.</p></div><div><h3>Results</h3><p>A total of 6 randomized clinical trials comprising 1162 patients were included in our analysis. In the individual patient data (IPD) pooled analysis, a significant OS benefit was found for nCRT in ESCC (HR=0.81, 95 %CI:0.67–0.98, p=0.029), compared with the treatment of nCT. The median overall survival time were 53 months (95 %CI:41.9–67.7 m) and 66 months(95 %CI:57.2-NA) respectively in the nCT and nCRT groups. Additionally, a significant improvement in PFS for nCRT compared to nCT in the IPD pooled analysis (HR=0.79,95 %CI:0.64–0.98; p=0.027). Consistent with above results, the pooled HRs of OS and DFS for nCRT versus nCT were 0.78 (95 % CI 0.65–0.92, p=0.004) and 0.79 (95 % CI: 0.65–0.97, p=0.02), respectively. Notably, no substantial heterogeneity across studies was observed.</p></div><div><h3>Conclusions</h3><p>Our findings indicate that nCRT offers better survival outcomes for ESCC, at least when compared to neoadjuvant doublet chemotherapy.This evidence continues to support the clinical practice of employing nCRT in locally advanced resectable ESCC.</p></div>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":null,"pages":null},"PeriodicalIF":4.9,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142111433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Single pre-operative radiation therapy (SPORT-CK) trial for low-risk breast cancer: Early results of a phase 2 study 低风险乳腺癌术前单次放疗（SPORT-CK）试验：2 期研究的早期结果。

IF 4.9 1区医学 Q1 ONCOLOGY

Radiotherapy and Oncology

Pub Date : 2024-08-30 DOI: 10.1016/j.radonc.2024.110510

Background and purpose

Preoperative partial breast irradiation (PBI) is a novel technique that can be used in patients with early-stage breast cancer with the goal of limiting the irradiated breast volume, toxicity and number of fractions. The aim of this trial is to assess the toxicity, surgical, oncologic and cosmetic outcomes of preoperative PBI.

Materials and Methods

In this single-arm phase II trial, we enrolled women ≥ 60 years, with unifocal low-risk breast invasive ductal carcinoma (cT1N0, grade 1–2, ER+, Her2-). Patients were treated with a single fraction of 20 Gy of preoperative PBI using volumetric modulated arc therapy (VMAT). Patients then underwent breast-conserving surgery (BCS) +/- sentinel lymph node biopsy within 72 h of radiation. Primary outcomes were rate of surgical complications and early toxicity. Secondary outcomes were cosmesis at 12 months, chronic toxicity and ipsilateral breast tumor recurrence.

Results

Twenty-five patients were recruited with a median age of 67 years, and a median follow-up of 60 months. Sentinel biopsy was positive in 1 out of 24 patients (4 %). Two patients received adjuvant RT for close margins or positive lymph nodes. Within the first 90 days, none of the patients had surgical complications; almost all had grade 0 to 1 acute and late RTOG skin toxicity. The cosmetic outcome was rated between good and excellent in all cases by physicians and patients, except for one patient who self-rated her cosmesis as fair as of the third year. There were no recurrences.

Conclusion

Preoperative single-fraction PBI is a safe and feasible treatment for elderly patients with low-risk early-stage breast cancer, with no surgical complications, very low rates of acute and late radiation toxicity, and excellent cosmetic outcomes. Randomized controlled trials are needed to compare preoperative to adjuvant PBI in this patient population.

背景和目的：术前乳腺部分照射（PBI）是一种新技术，可用于早期乳腺癌患者，目的是限制照射乳房的体积、毒性和分次次数。本试验旨在评估术前 PBI 的毒性、手术、肿瘤和美容效果：在这项单臂 II 期试验中，我们招募了年龄≥ 60 岁、患有单灶低危乳腺浸润性导管癌（cT1N0、1-2 级、ER+、Her2-）的女性患者。患者在术前使用体积调制弧疗法（VMAT）进行单次20 Gy的PBI治疗。然后，患者在放疗后 72 小时内接受保乳手术 (BCS) +/- 前哨淋巴结活检。主要结果是手术并发症发生率和早期毒性。次要结果是 12 个月后的外观、慢性毒性和同侧乳腺肿瘤复发：共招募了 25 名患者，中位年龄为 67 岁，中位随访时间为 60 个月。24 例患者中有 1 例（4%）前哨活检呈阳性。两名患者因边缘较近或淋巴结阳性而接受了辅助 RT 治疗。在最初的 90 天内，没有一名患者出现手术并发症；几乎所有患者都出现了 0 至 1 级急性和晚期 RTOG 皮肤毒性。医生和患者对所有病例的美容效果评价都在良好和优秀之间，只有一名患者在术后第三年自评美容效果一般。无一例复发：结论：对于低风险早期乳腺癌老年患者来说，术前单次分次PBI是一种安全可行的治疗方法，无手术并发症，急性和晚期放射毒性发生率极低，且美容效果极佳。需要进行随机对照试验，以比较术前和辅助 PBI 对这类患者的治疗效果。

{"title":"Single pre-operative radiation therapy (SPORT-CK) trial for low-risk breast cancer: Early results of a phase 2 study","authors":"","doi":"10.1016/j.radonc.2024.110510","DOIUrl":"10.1016/j.radonc.2024.110510","url":null,"abstract":"<div><h3>Background and purpose</h3><p>Preoperative partial breast irradiation (PBI) is a novel technique that can be used in patients with early-stage breast cancer with the goal of limiting the irradiated breast volume, toxicity and number of fractions. The aim of this trial is to assess the toxicity, surgical, oncologic and cosmetic outcomes of preoperative PBI.</p></div><div><h3>Materials and Methods</h3><p>In this single-arm phase II trial, we enrolled women ≥ 60 years, with unifocal low-risk breast invasive ductal carcinoma (cT1N0, grade 1–2, ER+, Her2-). Patients were treated with a single fraction of 20 Gy of preoperative PBI using volumetric modulated arc therapy (VMAT). Patients then underwent breast-conserving surgery (BCS) +/- sentinel lymph node biopsy within 72 h of radiation. Primary outcomes were rate of surgical complications and early toxicity. Secondary outcomes were cosmesis at 12 months, chronic toxicity and ipsilateral breast tumor recurrence.</p></div><div><h3>Results</h3><p>Twenty-five patients were recruited with a median age of 67 years, and a median follow-up of 60 months. Sentinel biopsy was positive in 1 out of 24 patients (4 %). Two patients received adjuvant RT for close margins or positive lymph nodes. Within the first 90 days, none of the patients had surgical complications; almost all had grade 0 to 1 acute and late RTOG skin toxicity. The cosmetic outcome was rated between good and excellent in all cases by physicians and patients, except for one patient who self-rated her cosmesis as fair as of the third year. There were no recurrences.</p></div><div><h3>Conclusion</h3><p>Preoperative single-fraction PBI is a safe and feasible treatment for elderly patients with low-risk early-stage breast cancer, with no surgical complications, very low rates of acute and late radiation toxicity, and excellent cosmetic outcomes. Randomized controlled trials are needed to compare preoperative to adjuvant PBI in this patient population.</p></div>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":null,"pages":null},"PeriodicalIF":4.9,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0167814024034881/pdfft?md5=96b8ea3a2256a9ee5ca7da9ea211752c&pid=1-s2.0-S0167814024034881-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142111431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

3484: RAPTOR project: Verification 3484:RAPTOR 项目：验证

IF 5.7 1区医学 Q1 ONCOLOGY

Radiotherapy and Oncology

Pub Date : 2024-08-30 DOI: 10.1016/s0167-8140(24)03411-x

Jacob Brunner

引用次数: 0

3510: What every physicist should know about commissioning TG-43- and model-based treatment planning systems in brachytherapy 3510:在近距离放射治疗中调试基于 TG-43 和模型的治疗计划系统时，每位物理学家都应了解的知识

IF 5.7 1区医学 Q1 ONCOLOGY

Radiotherapy and Oncology

Pub Date : 2024-08-30 DOI: 10.1016/s0167-8140(24)03432-7

Javier Vijande

引用次数: 0

3490: Risk-adapted and response-adapted strategies for stage 3 NSCLC 3490:针对 3 期 NSCLC 的风险适应和反应适应策略

IF 5.7 1区医学 Q1 ONCOLOGY

Radiotherapy and Oncology

Pub Date : 2024-08-30 DOI: 10.1016/s0167-8140(24)03416-9

Andrea Riccardo Filippi

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Radiotherapy and Oncology

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀